Well-differentiated digestive neuroendocrine tumors (NET) are a heterogeneous group of neoplasms usually associated with slow growth but a high rate of metastases, including peritoneal carcinomatosis (PC). Herein, we aimed to comprehensively review the current knowledge of PC in terms of implications for the management and prognosis of patients with NET, including the latest studies and expert statements. NET-derived PC concerns about 17% of NET patients and up to 30% of those with small intestine primary NET. It has an independent pejorative prognostic impact. The extent of PC in NET patients and its severity can be expressed by analogy to other malignancies. However, it must be placed in the context of NET disorders, which usually vary from other PC-related malignancies. Recently, a gravity PC score was proposed by a consensus European Neuroendocrine Tumor Society (ENETS) expert group, but it requires validation. In addition, the form of peritoneal involvement (nodular or fusiform/infiltrative) might influence its prognosis and management. Aggressive surgical management seems justified for subsets of NET-related PC but requires careful selection of the candidates most likely to benefit. Cytoreductive surgery prolongs survival, especially when the peritoneal lesions are completely resected. Too little is known about the benefit of hyperthermic intraperitoneal chemotherapy for NET-derived PC, but if it confers an advantage, it would have to be counterbalanced by its high morbidity.

Keywords:
Peritoneal carcinomatosis, Neuroendocrine tumors, Metastases, Prognosis, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy
1.
Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G, Borson-Chazot F, Aparicio T, Ducreux M, Lecomte T, Etienne PL, Cacheux W, Legoux JL, Seitz JF, Ruszniewski P, Chayvialle JA, Rougier P: Thirteen-month registration of patients with gastroenteropancreatic endocrine tumors in France. Neuroendocrinology 2009;89:217-222.
2.
Walter T, Scoazec J-Y, Lepage C: Epidemiology of digestive neuroendocrine tumors with focus on French data. Hépato-Gastro 2013;20:160-166.
3.
Vasseur B, Cadiot G, Zins M, Fléjou JF, Belghiti J, Marmuse JP, Vilgrain V, Bernades P, Mignon M, Ruszniewski P: Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer 1996;78:1686-1692.
4.
Elias D, Sideris L, Liberale G, Ducreux M, Malka D, Lasser P, Duvillard P, Baudin E: Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 2005;137:411-416.
5.
Pape U-F, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, Willich S, Wiedenmann B: Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083-1097.
6.
Strosberg J, Gardner N, Kvols L: Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009;89:471-476.
7.
Bhosale P, Shah A, Wei W, Varadhachary G, Johnson V, Shah V, Kundra V: Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. Eur Radiol 2013;23:400-407.
8.
Chambers AJ, Pasieka JL, Dixon E, Rorstad O: The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery 2008;144:645-653.
9.
Norlén O, Stålberg P, Öberg K, Eriksson J, Hedberg J, Hessman O, Janson ET, Hellman P, Åkerström G: Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 2012;36:1419-1431.
10.
Kianmanesh R, Ruszniewski P, Rindi G, Kwekkeboom D, Pape U-F, Kulke M, Sevilla Garcia I, Scoazec JY, Nilsson O, Fazio N, Lesurtel M, Chen YJ, Eriksson B, Cioppi F, O'Toole D: ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology 2010;91:333-340.
11.
Gilly FN, Cotte E, Brigand C, Monneuse O, Beaujard AC, Freyer G, Glehen O: Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol 2006;32:597-601.
12.
Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359-374.
13.
Swellengrebel HAM, Zoetmulder FAN, Smeenk RM, Antonini N, Verwaal VJ: Quantitative intra-operative assessment of peritoneal carcinomatosis: a comparison of three prognostic tools. Eur J Surg Oncol 2009;35:1078-1084.
14.
Au JT, Levine J, Aytaman A, Weber T, Serafini F: Management of peritoneal metastasis from neuroendocrine tumors. J Surg Oncol 2013;108:385-386.
15.
Brücher B, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Königsrainer A, Ströhlein M, Levine E, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A: Peritoneal carcinomatosis: cytoreductive surgery and HIPEC: overview and basics. Cancer Invest 2012;30:209-24.
16.
Rivard J, Temple W, McConnell Y, Sultan H, Mack L: Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis. Am J Surg 2014;207:760-765.
17.
Sommariva A, Zagonel V, Rossi CR: The role of laparoscopy in peritoneal surface malignancies selected for hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2012;19:3737-3744.
18.
Iversen LH, Rasmussen PC, Laurberg S: Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 2013;100:285-292.
19.
Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W: Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005;241:839-845.
20.
Makridis C, Rastad J, Oberg K, Akerström G: Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 1996;20:900-906.
21.
Ohrvall U, Eriksson B, Juhlin C, Karacagil S, Rastad J, Hellman P, Åkerström G: Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 2000;24:1402-1408.
22.
Hellman P, Lundström T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, Janson ET, Åkerström G: Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002;26:991-997.
23.
Akerström G, Hellman P, Hessman O: Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 2005;19:717-728.
24.
de Mestier L, Neuzillet C, Hentic O, Kianmanesh R, Hammel P, Ruszniewski P: Prolonged survival in a patient with neuroendocrine tumor of the cecum and diffuse peritoneal carcinomatosis. Case Rep Gastroenterol 2012;6:205-210.
25.
Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet J-F, Dromain C, Schlumberger M, Pocard M, Boige V, Miquel C, Baudin E: Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 2003;133:375-382.
26.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D: Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010;116:5608-5618.
27.
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder F: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-3743.
28.
Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, Stoclin A, Malka D, Boige V, Ducreux M: Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 2014;50:332-340.
29.
Glehen O, Mohamed F, Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219-228.
30.
Glockzin G, Schlitt HJ, Piso P: Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2009;7:5.
31.
Elias D, David A, Sourrouille I, Honoré C, Goéré D, Dumont F, Stoclin A, Baudin E: Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases). Surgery 2014;155:5-12.
32.
Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B: Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007;14:509-514.
33.
Quenet F, Goéré D, Mehta SS, Roca L, Dumont F, Hessissen M, Saint-Aubert B, Elias D: Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 2011;254:294-301.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.